Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to Editors

Should we screen Eastern Mediterranean COVID-19 patients for inherited thrombophilia?

ARTICLE INFO

Keywords
COVID-19
Inherited thrombophilia
Thrombosis
Anticoagulation

ABSTRACT

The inflammatory component of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) creates a pro-thrombotic state that necessitates a thrombophylactic strategy for hospitalized patients. Such strategies are difficult to be standardized because certain individuals can have pro-thrombotic conditions, such as inherited thrombophilia, which pre-dispose them to an additional coagulative risk. Whether outside the hospital or when admitted, patients with inherited thrombophilia need special anticoagulant and antiplatelet attention. Identifying such patients, especially in susceptible populations like the eastern Mediterranean (EM) region, will aid primary providers in risk stratification for choosing the optimal anticoagulation or antiplatelet plan.

To the editor.

Background

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) targets the Angiotensin converting enzyme (ACE)-2 protein [1], which is present on the cell surface membrane of several body tissues, such as lung alveolar epithelial cells, enterocytes of the small intestine, arterial and venous endothelial cells, arterial smooth muscle cells, and epithelia of the lung and small intestine [2]. This epithelial expression, together with the presence of ACE2 in vascular endothelium [3], causing a massive release of proinflammatory cytokines, promoting a cytokine storm [4]. The inflammatory milieu abnormally activates the coagulative system manifesting as macro and micro thrombosis [5]. As a result, patients infected with SARS-CoV-2 are in need to be risk stratified accordingly in order to decide on a strategy for thrombophylaxis if needed. Many strategies and scores have been suggested, such as those by the American Society of Hematology [6] and the International Society on Thrombosis and Haemostasis [7]. However, it is difficult to apply the same guidelines to different regions of the world with different pro-thrombotic profiles. Examples of such conditions include Eastern Mediterranean (EM) patients with inherited thrombophilia, such as C677T polymorphism of MTHFR had been associated with specific vulnerability to a severe course of Coronavirus disease 2019 (COVID-19) initiated by hyperhomocysteinemia [12]. Likewise, increased activity in factor V had been reported in critically ill [13], as well as non-critically ill patients [14], leading to predisposition for thrombosis. Factor II prothrombin G20210A is also associated with prothrombotic state [15], and has been linked to DVT and pulmonary embolism (PE) in COVID-19 patients [16].

Prevalence

Eastern Mediterranean countries exhibit higher prevalence of major thrombophilia genetic mutations than other worldwide regions. For example, 14.4% of apparently healthy Lebanese people, and 40% of Lebanese patients with deep vein thrombosis (DVT), are carriers of specific point mutation (G1691 to A; Arg506–Gln) in the factor V gene [8]. The prevalence of heterozygosity for factor V Leiden gene mutation among the EM countries is similar to Lebanon (Table 1). Likewise, the prevalence of carriers of the MTHFR C677T genotypes was estimated to be in the range of 10–34% among Lebanese healthy individuals [9], while those carrying homozygous mutation of MTHFR C677T genotype constituted 11% of the population [10]. Furthermore, prothrombin G20210A heterozygous mutation was found in 3% of healthy Lebanese individuals and 12.5% in Lebanese DVT patients [9]. One mutation in each of the three major thrombophilia genes, or triple mutation, happens in 1.1% of the population [11]. With this presumably high prevalence of major thrombophilia genetic mutations among the EM population, infection with SARS-CoV-2 predisposes such vulnerable population to higher thrombosis risk.

COVID-19

The C677T polymorphism of MTHFR had been associated with specific vulnerability to a severe course of Coronavirus disease 2019 (COVID-19) initiated by hyperhomocysteinemia [12]. Likewise, increased activity in factor V had been reported in critically ill [13], as well as non-critically ill patients [14], leading to predisposition for thrombosis. Factor II prothrombin G20210A is also associated with prothrombotic state [15], and has been linked to DVT and pulmonary embolism (PE) in COVID-19 patients [16].

Hypothesis

Despite the data supporting a higher risk for thrombosis in EM COVID-19 patients, the thrombophylactic regimens stay unclear. It is important to list all the risk factors along with the clinical presentation. Patients with previous thrombotic complications, familial history, pregnancy, estroprogestative treatment, and air travel are at higher risk [17]. In addition, the presence of a homozygous genetic mutation places the patient at higher risk of thrombosis than a heterozygous mutation patient [18]. Therefore, the risk of thrombosis should be based on the clinical symptoms and laboratory data. As a result, the anticoagulation/antiplatelet choice will depend on several factors and profiles as illustrated (Fig. 1).

However, it is still unknown whether EM COVID-19 patients with no confirmed thrombophilia should be managed similarly to thrombophilia...
patients. It might be impractical to screen every COVID-19 patient for thrombophilia in order to stratify the risk of thrombosis. Therefore, the choice of anticoagulation should be taken on a case-by-case basis depending on the personal and familial medical history. There are several thrombophylactic options present, and these depend on the clinical profile of each patient. A stratified risk score could benefit physicians in order to guide them in thrombophylactic regimens. Further randomized clinical trials are needed to determine anticoagulation options for different scenarios and to study new options such as the novel oral anticoagulants.

Consent statement/ethical approval

Not required.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020;525(1):135–40.
[2] Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203(2):631–7.
[3] Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367(6483):1260–3.

[4] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061. https://doi.org/10.1001/jama.2020.1585.

[5] Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. Arch Pharm Res 2021;44(1):99–116.

[6] Spyropoulos AC. 2020. The management of venous thromboembolism in hospitalized patients with COVID-19. Blood Adv 4:4028.

[7] Marchandot B, Trémisaille A, Cartiaux A, Matsushita K, Jesel I, Morel O. Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic. J Thromb Thrombolysis 2020;50(4):799–808.

[8] Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000;65(1):45–9.

[9] Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 2001;86(08):723–4.

[10] Almawi WY, Finan RR, Tamim H, Daccache JL, Irani-Hakime N. Differences in the frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene among the Lebanese population. Am J Hematol 2004;76(1):85–7.

[11] Hotte R, Taher A, Nassar R, Ottrock Z, Halawi R, Mahfouz RAR. Frequency of triple mutations involving factor V, prothrombin, and methylenetetrahydrofolate reductase genes among patients referred for molecular thrombophilia workup in a tertiary care center in Lebanon. Genet Test Mol Biomarkers 2012;16(3):223–5.

[12] Karst M, Hollenhorst J, Achenbach J. Life-threatening course in coronavirus disease 2019 (COVID-19): Is there a link to methylenetetrahydrofolate acid reductase (MTHFR) polymorphism and hyperhomocysteinemia? Med Hypotheses 2020;144:110234.

[13] Steffey JA, Christensen BB, Gogakos T, Cone Sullivan JK, Montgomery GG, et al. Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism. Am J Hematol 2020;95:1522–30.

[14] Meijenfeldt FA, Havervall S, Adelmeijer J, Lundström A, Magnusson M, Mackman N, et al. Elevated factor V activity and antigen levels in patients with COVID-19 are related to disease severity and 30-day mortality. Am J Hematol 2021;96(4).

[15] Girolami A, Cosi E, Ferrari S, Girolami B. Prothrombin: another clotting factor after FV that is involved both in bleeding and thrombosis. Clin Appl Thromb Hemost 2018;24(6):845–9.

[16] Morena-Barrio ME, Bravo-Pérez G, Morena-Barrio B, Orlando C, Cifuentes R, Padilla J, et al. A pilot study on the impact of congenital thrombophilia in COVID-19. Eur J Clin 2021;53(5):e13546.

[17] Kreidy R, Irani-Hakime N. Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients? Vasc Health Risk Manag 2009;5:627–33.

[18] Federici EH, Al-Mondhary H. High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A. Thromb Res 2019;182:75–8.

[19] Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346(8983):1133–4.

[20] Awidi A, Shammak M, Beiso A, Kailani MAM, Kailani MA, Omar N, et al. High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 1999;81(04):582–4.

[21] Gurgey A, Mesi L. The prevalence of factor V Leiden (1691 G–>A) mutation in Turkey. Turk J Pediatr 1997;39:313–5.

Georges El Hasbani, Ali T. Taher*  
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon  
* Corresponding author.  
E-mail address: ataither@aub.edu.lb (A.T. Taher).